Clinical Trial Update: Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial update for Sym023 (anti-TIM-3) in patients with advanced solid tumors, metastatic cancer, or lymphomas; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lymphoma
• Solid Tumors

Drugs mentioned

• Sym023

Snippet

Sponsor: Symphogen A/S | Conditions: Metastatic Cancer, Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2021-10-12